Citations

Clear

313 citation(s) found for "Alvarez, P".

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy
Vannucchi, Alessandro Maria, Gale, Robert Peter, Harrison, Claire, Hehlmann, Rüdiger , Tefferi, Ayalew , Barbui, Tiziano , Marchetti, Monia , Vannucchi, Alessandro M. , Mascarenhas, John , Álvarez‐Larrán, Alberto , Bose, Prithviraj , Kiladjian, Jean‐Jacques , Koschmieder, Steffen , Mesa, Ruben A. , Passamonti, Francesco , Rambaldi, Alessandro

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7898-7898

10.1182/blood-2024-198646 Get It

Background New therapies for myelofibrosis (MF) are being developed but how these compare with current therapies is limited to analyzing single outcome measures such as spleen volume reduction or quality-of-life (QoL). However, these outcome trajectories might diverge and some endpoints may not be clinically relevant. To remedy this an ELN (European LeukemiaNet) taskforce developed a composite endpoint using the Desirability-Of-Outcome-Ranking (DOOR) method which allows multiple outcomes to be simultaneously considered and therapies achieving diverging endpoints compared. Methods An Expert Panel used DOOR to divide outcome relevancy into 8 dimensions: clinical meaningfulness, modifiability, reliability, feasibility, decisional value, acceptability, frequency, and cost. Next, a weight was assigned to each dimension using the mean Likert score assigned by the panelists. Next, the panel validated which dimensions were met by each of 30 outcomes most frequently listed by clinical trials. A weighted score (WS) for each outcome was calculated based on weights assigned to a dimension and accomplishment rates assigned to outcomes. Outcomes were then distributed into quartiles. Next, operational definitions of outcomes were tested in Delphi consensus method requiring > 75% agreement. Last, a literature review indicated correlations of the outcomes ranked in the 1st 2 quartiles with survival. Results Three composite endpoints were developed and named DEMYOs (DEsirability-of-MYelofibrosis-Outcomes). DEMYO-1, the proportion of people alive and free of severe vascular events, blast transformation, severe anaemia and thrombocytopenia and very-severe symptom burden, encompassed outcomes in the 1st quartile (WS > 29.5) and is the proposed composite endpoint for trials of people with advanced JAK-inhibitor refractory MF. DEMYO-2, defined as the proportion of people alive and free of accelerated or blast phase, severe or worsening anaemia, severe and major vascular events, severe or symptomatic splenomegaly, severe or worsening symptoms and any emergent adverse genetic abnormality, included the outcomes ranked in the 1st 2 quartiles (WS > 26.5) and is proposed for trials of people with a sub-optimal response to JAK-inhibitors. DEMYO-3, defined as the proportion of people alive and free of blast transformation, vascular events, severe, symptomatic or worsening clinical features and of worsening prognostic co-variates, included outcomes in the 1st 3 quartiles (WS > 23.5) and is proposed for trials of people not yet receiving JAK-inhibitors. Interpretation DEMYO composite endpoints capture relevant clinical features of MF and represent endpoints important to patients, physicians and other stakeholders. DEMYO validation is feasible by available trial data and, once validated, the composite endpoints can be endorsed by medicines regulatory agencies. DOOR proved feasible and robust in this 1st-in-haematology application and we encourage further use. No funding
Methodological limitations in the systematic review of rheumatic adverse events associated with biologic therapy for chronic rhinosinusitis
Moreno‐Peña, Pablo J. , Treviño‐González, José Luis , Alvarez-Villalobos, Neri Alejandro, Álvarez‐Villalobos, Neri Alejandro

Mayo Clinic

International Forum of Allergy & Rhinology | December 3, 2024 | Volume: 15 | Issue: 1 | Pages: 95-96

10.1002/alr.23498 | PMID 39624912 Get It

Pleural space infection microbiology as assessed using a clinical sequencing-based assay: Fusobacterium nucleatum group, Streptococcus intermedius, and other oral normal microbiota are the most
Otero, Judith Álvarez , Mandrekar, Jay , Wolf, Matt J., Starkey, Jordan C., Carmona, Eva M. , Kommedal, Øyvind , Patel, Robin , Alvarez Otero, Judith , Patel, Robin , Carmona, Eva M , Dyrhovden, Ruben

Mayo Clinic

Journal of Clinical Microbiology | November 25, 2024 | Volume: 62 | Issue: 12 | Pages: No page available

10.1128/jcm.00694-24 | PMID 39584837 Get It

ABSTRACT The definition of the microbiology of pleural space infection has been challenging due to the poor yield of conventional culture. Here, the results of a 16S ribosomal RNA gene PCR/sequencing assay performed on pleural fluid in routine clinical practice between August 2020 and January 2023 were evaluated. Amplified 16S rRNA gene DNA was submitted to Sanger sequencing and/or next-generation sequencing or results were reported as negative, depending on PCR crossing threshold value. In all, 496 pleural fluids were tested at Mayo Clinic Laboratories, with 227 positive results, including 57 from Mayo Clinic patients. Among the 57 Mayo Clinic patients, pleural space infection was community acquired in 48 (84%); Fusobacterium nucleatum group and/or Streptococcus intermedius were detected in 31/57 (54%) cases [including 28/48 (58%) community-acquired cases], with additional facultative and/or anaerobic species also found in various combinations in 17/31 (55%). Results of this study suggest that the most frequent microorganism profile involved in community-acquired pleural space infection may be a combination of F. nucleatum group and/or S. intermedius , with or without other normal microbiota. IMPORTANCE We describe here the most frequent microorganisms detected in community-acquired pleural space infection using a clinically performed sequencing-based assay. We found that the most common detection was the Fusobacterium nucleatum group and/or Streptococcus intermedius , with or without other normal microbiota. We propose the term e-FuSion (effusion with Fusobacterium nucleatum group, Streptococcus intermedius , and other oral normal microbiota) for this entity.
Evaluating the metformin use on type 2 diabetes prevention in high-risk populations in primary care
Ramírez-Torres, Andony I., Ruiz-Hernández, Fernando G. , Omaña, Gabriela Guadalupe Elizondo, García-Hernández, Rosa María , Peña, P. García de la, Rojo-Garza, Sandra S., Ruiz Hernandez, Fernando Gerardo , Álvarez‐Villalobos, Neri Alejandro , García-Hernández, Rosa M., Peña, Pablo J. Moreno

Mayo Clinic

Journal of Family Medicine and Primary Care | November 16, 2024 | Volume: 13 | Issue: 11 | Pages: 5002-5008

10.4103/jfmpc.jfmpc_552_24 | PMID 39722964 Get It

A BSTRACT Purpose/Background: To identify the proportion of patients with prediabetes who have prescribed metformin and factors related to doing so as a preventive measure for diabetes in primary care at a Family Medicine Unit in northeastern Mexico. Methods: This retrospective observational study included 372 adults who met the criteria for prediabetes diagnosis according to the American Diabetes Association. Data was collected from medical records from January 2020 to December 2021. Possible associations between the variables of interest and the prescription of metformin were tested via hypothesis tests, furthermore, binary logistic regression was performed. Results: Nearly 85% of the patients met at least one criterion for receiving metformin according to ADA recommendations, but only 60% of them were prescribed this medication. Patients with metformin prescriptions differed from those without in aspects such as having a documented diagnosis of prediabetes in their medical records, a higher BMI, and higher glucose levels. Conclusions: Almost one out of two patients with a high risk of type 2 diabetes are not treated with metformin as a preventive measure. Factors associated with metformin prescription included a high BMI, elevated baseline glucose levels, and a prediabetes diagnosis in the medical record. These findings suggest the need for studies to evaluate physicians’ reasons for different treatments and implementation of recommendations for type 2 diabetes prevention in patients with prediabetes in primary health care.
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, Alessandro , Petersen, René Horsleben , Stiles, Brendon M. , Wigle, Dennis A. , Collaborators, Platz, Joseph , Muesse, Jason , Grenda, Tyler R., Makey, Ian A. , Khandhar, Sandeep J. , Schipper, Paul H., Linsky, Paul L., Liptay, Michael J, Pechet, Taine, White, Abby , Wood, Douglas E. , Brandt, Whitney S. , Martin, Linda D., Patterson, Alec, Seder, Christopher W. , Lanita, Michael, Molena, Daniela , Lee, Jay M. , Healy, David , Decker, G. Anton , Sihoe, Alan , Zairi, Sarra , Dunning, Joel , Raveglia, Federico , Kleontas, Athanasios, Szántó, Zalán , Nosotti, Mario , Hudson, Jessica , Schneiter, Didier, Asadi, Nizar , Aranda, J.M. Botía, Congregado, Miguel , Backhus, Leah, Bertani, Alessandro , Nadal, Sergio Bolufer, Rosso, Lorenzo, Gattás, Gustavo, Augustin, Florian , Milton, Richard , Vannucci, Fernando , Waller, David , Gasparri, Mario, Reddy, Rishindra M. , Schreurs, W. H. , Saftić, Igor, Scarci, Marco, Toker, Seyfi Alper, Welcker, K , Furák, József, Durand, Marion, Hugen, Niek , Joseph, Lula Lukadi, Chiappetta, Marco , Pérez, María Rodríguez, Minasyan, Anna , Filose, Pier Luigi, Elkhayat, Hussein , Wei, Benjamin , Leone, Richard J., Chang, Albert S., Curcio, Carlo, Sparks, Preston, Hagen, Jeffrey A., Baste, Jean Marc , Taylor, Lauren , Xavier, D'journo, Hall, David Jeffrey, Hansen, Henrik Jessen, Leschber, Gunda, Koryllos, Aris , Gandhi, Shilpa , Batgirl, Hasan, Calvin, Ng Sze Hang, Sotiropoulos, Georgios C. , Furrer, Markus , Danjouma, Cheufou, Novoa, Nuria , Cassivi, Stephen D. , Veronesi, Giulia , Hamouri, Shadi , Štupnik, Tomaž , Hall, David J. , Antonoff, Mara B. , Collaborators, Louie, Brian E. , Daddi, Niccolò , Swisher, Stephen G. , Yendamuri, Sai S , Liptay, Michael J, Herrera, Luis, Martin, Linda, Patterson, Alec, Sandri, Alberto , Ruffini, Enrico , Maurizi, Giulio , Kleontas, Athanasios, Depypere, Lieven , Caruana, Edward Joseph , Mitchell, John , Gonfiotti, Alessandro , Pagès, P , Aranda, Jose, Billè, Andrea , Falcoz, Pierre‐Emmanuel , Rosso, Lorenzo , Terra, Ricardo Mingarini , Raemdonck, Dirk Van , Minervini, Fabrizio , Tosi, Davide , Solli, Piergiorgio , Scarci, Marco , Gooseman, Michael , Gossot, Dominique , Álvarez, Antonio , Toker, Seyfi Alper, Aramini, Beatrice , Guerrera, Francesco , Jiménez, Marcelo Fernando , Bölükbas, Servet , Thomas, P. A. , Luzzi, Luca , Aigner, Clemens , Minasyan, Anna, Kim, Young Tae , Pompili, Cecilia , Shargall, Yaron , Fiorelli, Alfonso , Curcio, Carlo, Bilfinger, Thomas V. , Engelhardt, Kathryn Elizabeth , Hall, David Jeffrey, Akopov, Andrey L. , Loos, Erik Robert de , Karamustafaoğlu, Yekta Altemur , Bertolaccini, Luca , Hendriks, Jeroen M. , Scanagatta, Paolo , Prisciandaro, Elena , Gómez-Hernández, María Teresa , Agrafiotis, Apostolos C. , Casiraghi, Monica , Danjouma, Cheufou Housmanou, Mariani, Alessandro Wasum , Antonio, David Gómez de , Bolca, Ciprian Nicolae , Cattaneo, Margherita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 15, 2024 | Volume: 66 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezae344 | PMID 39545513 Get It

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519

10.6004/jnccn.2024.0052 | PMID 39413835 Get It

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Immune checkpoint dysregulation in COVID-19 pathogenesis and disease severity.
Villalba, Julian A. , Shih, Angela , Alba, George A. , Loyola-Rodríguez, Georgina, Alcántara, Ismael Ramírez, Ferreira, Luíz Carlos de Lima , Stigliano, Egidio, Hirschbühl, Klaus , Argueta, Allan , Ackermann, Maximillian , Werlein, Christopher , Uribe‐Uribe, Norma , Vázquez-Benítez, Greissy, Tzankov, Alexandar , Stalder, Anna K. , Francesqui, Joel , Osborn, Michael , Hanley, Brian , Johnston, Robert, Lacy, J. Matthew , Marshall, Desiree A. , Schwensen, Hanna Ferløv , Okudela, Koji , Flikweert, Antine, Iles, Linda , d’Amati, Giulia , Träger, Lene Hoffmann , Çınar, Hüseyin, Aguiar, Diego , Dolhnokoff, Marisa, Chilosi, Marco , Salmon, I, Colville‐Ebeling, Bonnie, Poissy, Julien , Haahr, Martha Kirstine , Reyes, Fabiola, Parry, Blair A. , Garlin, Michelle, Hilburn, Caroline F., ELLIOTT, G. A., Rosas, Iván O. , Sade-Feldman, Moshe , Hacohen, Nir , Baden, Lindsey R. , Li, Jonathan Z. , Schaller, Tina , Gigli, L, Macciò, Umberto , Yick, David C.Y., Bruni, Barbara, Pernazza, Angelina , Mauad, Thaís , Dubini, Alessandra, Hartmann, Arndt, Remmelink, Myriam , Aviles, Alexis J., Barth, Jamie L., Boyraz, Bariş , Araujo-Medina, Milagros, Mendez-Pena, Javier E., Chebib, Ivan , Hung, Yin P. , Rosales, Ivy A. , Smith, Rex-Neal, Hung, Yin P , Tzankov, Alexandar , Li, Yijia , Poli, Sergio , Kunitoki, Keiko , Mehta, Arnav , Santana, Monique Freire , Lacerda, Marcus , Dell’Aquila, Marco , Arena, Vincenzo , Calabrese, Fiorella , Pezzuto, Federica , Märkl, Bruno , Lozano, Maria, Jonigk, Danny David , Pomara, Cristoforo , Salerno, Monica , Salas, Clara , Martínez, Daniel, Parra-Medina, Rafael Santiago , Bradley, Benjamin T. , Chen, Sonja , Varga, Zsuzsanna , Steinestel, Konrad , Harper, Holly , Aiolfi, Alberto , Scendoni, Roberto , Fabro, Alexandre Todorovic , Doglioni, Claudio , Rossi, Giulio , Poletti, Venerino , Herrmann, Martin , Pugh, Matthew , Yan, Lei , Gentili, Matteo , Garlin, Michelle A., Lo, Ying‐Chun , Elliott, Grant, Martínez, Leonardo , Stone, James R. , Colvin, Robert B. , Goldberg, Marcia B. , Filbin, Michael R. , Mino-Kenudson, Mari A. , Kröncke, Thomas J. , Gigli, Laura Álvarez, Sessa, Francesco , Caltabiano, Rosario , Menter, Thomas , Sellarés, Jacobo , Storgaard, Merete , Hamilton‐Dutoit, Stephen , Dannheim, Katelyn , Witte, Hanno Maximilian , Bona, Davide , Leth, Peter Mygind , Banner, Jytte , Batah, Sabrina Setembre , Silva, Luiz Fernando Ferraz da , Duarte‐Neto, Amaro Nunes , Saldiva, Paulo Hilário Nascimento , Munoz, Luis Enrique , Jensen, T. , Brøchner, Christian Beltoft , Gibier, Jean‐Baptiste , Gilbert, Andrea , Madrigal, Emilio , Ly, Amy , Hariri, Lida P. , Caldwell, Nicholas J

Mayo Clinic

No container title available | October 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3508654/v1 Get It

Abstract Accumulating evidence suggests dysregulated immune checkpoint (IC) signaling can exacerbate COVID-19 severity, but the role of these molecules in the pathogenesis of fatal COVID-19-related diffuse alveolar damage (DAD) remains elusive. Understanding how IC proteins influence acute lung injury due to COVID-19 can provide insights into potential therapeutic strategies to modulate immune responses and improve patient outcomes. Here, in a single-center autopsy cohort, we determined the cellular localization of ICs in lung tissue from cases of fatal COVID-19, DAD-comparators, and non-fibrotic controls by using immunohistochemistry, and investigated their association with clinical outcomes. We expanded our findings by performing analyses of publicly available single-cell RNA sequencing datasets from patients with fatal COVID-19 and non-fibrotic controls. We demonstrated the presence of protein-protein interaction networks of ICs in the lung cellular niche by performing transcriptomic profiling of lung tissue-derived RNA counts from patients with fatal COVID-19. Further, we leveraged data from the largest international, multi-center COVID-19 autopsy cohort and validated that, among patients with fatal COVID-19, those with higher PD-L1/CD274 expression in lung endothelial cells had more rapid clinical deterioration. Lastly, in a cohort of individuals with early COVID-19, IC plasma protein levels were elevated in those with persistent SARS-CoV-2 RNAemia and adverse clinical outcomes. Collectively, our data provide unique pathological insights into the role of IC dysregulation and differential disease severity in COVID-19.
Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis
Elizalde-Jiménez, Itzel Guadalupe , Ruiz-Hernández, Fernando G. , Carmona‐Cruz, Silvia Angélica , Pastrana-Arellano, Elena, Romo‐González, Carolina , Garza, Eduardo Arias-de la, Ruiz-Hernández, Fernando Gerardo, Alvarez-Villalobos, Neri Alejandro, Ruiz Hernandez, Fernando Gerardo , Aquino-Andrade, Alejandra , Garza, Eduardo Arias de la , Álvarez‐Villalobos, Neri Alejandro , García‐Romero, María Teresa

Mayo Clinic

JAMA Dermatology | September 25, 2024 | Volume: 160 | Issue: 11 | Pages: 1171

10.1001/jamadermatol.2024.3360 | PMID 39320869 Get It

Importance Individuals with atopic dermatitis are frequently colonized and infected with Staphylococcus aureus . Empirical antibiotic therapy for individuals with atopic dermatitis is common, but data about the antimicrobial susceptibility profiles of S aureus strains isolated from these individuals are scarce for those living in particular geographic areas. Objective To determine the antimicrobial susceptibility of S aureus from individuals with atopic dermatitis and analyze differences according to the income level of the country of origin and the data collection period. Data Sources A meta-analysis of the literature was performed from the inception of the included databases (MEDLINE, Embase, Web of Science, Scopus, and Cochrane) to June 20, 2023, using predetermined Medical Subject Headings. Study Selection Studies were included if they reported antibiotic susceptibility profiles of 1 or more S aureus cutaneous isolates from individuals with atopic dermatitis. Articles written in English, Spanish, French, or German were included. Data Extraction and Synthesis Working in pairs, 6 of the authors conducted the data extraction. The guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) were followed. Main Outcomes and Measures The outcome of interest was antimicrobial susceptibility. Results A total of 61 studies reported 4091 S aureus isolates from individuals with atopic dermatitis. For 4 of the 11 commonly used antibiotics (36.4%), antimicrobial susceptibility was 85% or less, including for methicillin (binomial proportion, 0.85 [95% CI, 0.76-0.91]), erythromycin (binomial proportion, 0.73 [95% CI, 0.61-0.83]), fusidic acid (binomial proportion, 0.80 [95% CI, 0.62-0.91]), and clindamycin (binomial proportion, 0.79 [95% CI, 0.65-0.89]). Most studies (46; 75.4%) were conducted in high-income countries. Antimicrobial susceptibility to erythromycin, methicillin, and trimethoprim and sulfamethoxazole was significantly lower in lower middle–income countries and upper middle–income countries. Regarding the temporal trends, 33 studies (54.1%) reported data collected from 1998 to 2010. Antimicrobial susceptibility patterns have not changed over time. Conclusions and Relevance In this systematic review and meta-analysis, antimicrobial susceptibility of S aureus to β-lactams, erythromycin, clindamycin, and fusidic acid may be suboptimal for empirical use in individuals with atopic dermatitis. Significant differences in antimicrobial susceptibility patterns were found in high-income countries and in lower middle–income countries and upper middle–income countries for some antibiotics.
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
Seiffge, David , Group, STR-OAC LAAO, Macha, Kosmas , Takagi, Masahito, Arihiro, Shoji , Polymeris, Alexandros A. , Yoshimura, Sohei , Venti, Michele , Thilemann, Sebastian , Altavilla, Riccardo , Peters, Nils , Inoue, Manabu, Bobinger, Tobias , Agnelli, Giancarlo , Acciarresi, Monica, Jager, Hans, Bovi, Paolo, Schwab, Stefan , Registry, RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen Registry, and Verona, Aarnink, Errol W. , Fierro, Nicolai, Tondo, Claudio , Zieliński, Kamil , Korsholm, Kasper , Nielsen-Kudsk, Jens Erik, Caneiro‐Queija, Berenice, Benito‐González, Tomás , Holmes, David R. , Almakadma, Abdul H., Álvarez, Xavier Millán, Alla, Venkata , Agarwal, Himanshu , Paitazoglou, Christina , Freixa, Xavier , Cepas‐Guillén, Pedro , Chothia, Rashaad , Badejoko, Solomon O. , Bergmann, Martin , Spoon, Daniel B., Maddux, James T., Ram, Pradhum , Branca, Luca , Dijk, Vincent F. van , Rensing, Benno J. , Paciaroni, Maurizio , Kallmünzer, Bernd , Wilson, Duncan , Jäger, Hans Rolf , Korsholm, Kasper , Seiffge, David , Jäger, Hans Rolf , Cepas-Guillen, Pedro , Maarse, Moniek , Werring, David J. , Boersma, Lucas V.A. , Group, STR-OAC LAAO, Tsivgoulis, Georgios , Bonetti, Bruno , Alberti, Andrea , Ambler, Gareth , Bonati, Leo H. , Muir, Keith W. , Yamagami, Hiroshi, Inoue, Manabu , Brown, Martin M. , Sato, Shoichiro , Lyrer, Philippe A. , Marchis, Gian Marco De , Peper, Joyce , Simard, Trevor , Alkhouli, Mohamad , Registry, RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen Registry, and Verona, Mazzone, Patrizio , Beneduce, Alessandro , Gasperetti, Alessio , Pracoń, Radosław , Demkow, Marcin , Backer, Ole De , Nielsen‐Kudsk, Jens Erik , Estévez‐Loureiro, Rodrigo , Prado, Armando Pérez de , Nombela‐Franco, Luis , Salinas, Pablo , Berti, Sérgio , Romeo, Maria Rita , Arzamendi, Dabit , Eitel, Ingo , Bergmann, Martin W., El‐Chami, Mikhael F. , Adamo, Marianna , Suradi, Hussam , Zietz, Annaelle , Caso, Valeria , Koga, Masatoshi , Toyoda, Ḱazunori , Cappellari, Manuel , Engelter, Stefan T. , Swaans, Martin John

Mayo Clinic

JAMA Neurology | September 23, 2024 | Volume: 81 | Issue: 11 | Pages: 1150

10.1001/jamaneurol.2024.2882 | PMID 39374446 Get It

ImportancePatients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT.ObjectiveTo compare percutaneous LAAO with continuing OAT alone regarding stroke prevention in patients with AF who had a thromboembolic event despite taking OAT.Design, Setting, and ParticipantsThis cohort study was a propensity score–matched comparison of the STR-OAC LAAO cohort, an international collaboration of 21 sites combining patients from multiple prospective registries of patients who underwent LAAO between 2010 and 2022. STR-OAC LAAO cohort patients who had follow-up longer than 3 months were propensity score–matched to a previously published control cohort comprising patients from an established international collaboration of investigator-initiated prospective studies. This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient ischemic attack, and follow-up longer than 3 months who were taking OAT before the index event. Analyses were adjusted for imbalances in gender, age, hypertension, diabetes, and CHA2 DS2-VASc score.ExposureLeft atrial appendage occlusion vs continuation of oral anticoagulation therapy alone (control group).Main Outcomes and MeasuresThe primary outcome was time to first ischemic stroke.ResultsFour hundred thirty-three patients from the STR-OAC LAAO cohort (mean [SD] age, 72 [9] years; 171 [39%] females and 262 [61%] males; mean [SD] CHA2 DS2-VASc score, 5.0 [1.6]) were matched to 433 of 1140 patients (38%) from the control group. During 2-year follow-up, 50 patients experienced ischemic stroke: an annualized event rate of 2.8% per patient-year in the STR-OAC LAAO group vs 8.9% per patient-year in the control group. Left atrial appendage occlusion was associated with a lower risk of ischemic stroke (hazard ratio, 0.33; 95% CI, 0.19-0.58; P < .001) compared with the control group. After LAAO, OAT was discontinued in 290 patients (67%), and the remaining 143 patients (33%) continued OAT after LAAO as an adjunctive therapy.Conclusions and RelevanceIn patients with nonvalvular AF and a prior thromboembolic event despite taking OAT, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone. Randomized clinical trial data are needed to confirm that LAAO may be a promising treatment option for this population with a very high risk of stroke.
P.514: Clinical utility of 1:16 serum dilution as a predictor of response to therapeutic plasma exchange for HLA antibody-mediated rejection treatment and overall survival in lung transplant recipients: A two center study.
Elrefaei, Mohamed , Narula, Tathagat , Alvarez, Francisco , Cordova, Francis , Shigemura, Norihisa , Toyoda, Yoshiya , Timofeeva, Olga , Godbey, Elizabeth A. , Criner, Gerard J.

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001068772.95728.d8 Get It